Mark J. Holterman, Medical

The American Diabetes Association’s Two Research Awards


American Diabetes Association pic
American Diabetes Association

Mark Holterman, MD, has practiced pediatric surgery and studied regenerative medicine for several years. The CEO of Mariam Global Health, he splits his time between medical research, teaching surgery at the University of Illinois, and providing pediatric care to surgical patients at OSF St. Francis Medical Center. As testament to his successes in the field, Dr. Mark Holterman has earned several awards, including the Innovative Research Award from the American Diabetes Association, an organization committed to funding research into diabetes cures and prevention measures.

The American Diabetes Association offers two research awards to professionals: the Innovative Basic Science (IBS) award and the Innovative Clinical or Translational Science (ICTS) award.

Available to faculty members at any level, the IBS award is given to basic research that presents an innovative and new hypothesis. These hypotheses must be related to the pathophysiology or etiology of diabetes and demonstrate significant progress in terms of advancing diabetes treatment and prevention. The organization specifically encourages high-risk projects that have a larger potential for producing high-impact results.

Eligible applicants are authorized to work in the United States, and IBS award recipients receive up to $115,000 per year for a maximum of three years.

Meanwhile, the ICTS award grants recipients $200,000 per year for up to three years. This award is also limited to professionals who are authorized to work in the country, and it is given to research that presents innovative hypotheses and demonstrates a high probability of high-impact results. However, ICTS award recipient research must directly involve human data, samples, or subjects.

Mark J. Holterman, Medical

About Mesenchymal Stem Cells


Celltex pic

Mark Holterman, MD, teaches coursework in surgery and pediatrics as a professor at the University of Illinois College of Medicine at Peoria. An expert in cellular and regenerative therapies, Dr. Mark Holterman also helped to found the Alliance for the Advancement of Cellular Therapies and the Sunshine Foundation.

A charitable organization, the Sunshine Foundation was created to support cellular and regenerative therapies. It was inspired by three young individuals who received effective cellular and regenerative therapies. Celltex Therapeutics, a biotechnology firm, provided regenerative therapy for one of the individuals to treat systemic juvenile idiopathic arthritis and dysautonomia.

Celltex utilizes stem cells known as mesenchymal stem cells when conducting cellular therapy. Mesenchymal stem cells, also known as MSCs, can be readily found in tissue throughout the human body. Fat tissue is a plentiful source for MSCs, but they are often taken from bone marrow, umbilical cord blood, and placenta tissue as well.

MSCs have the ability to grow into many different cell types, such as bone and muscle, and play a role in combating inflammation, improving healing, stopping cellular decay, and forming new blood vessels. For additional information, visit

Mark J. Holterman, Medical

The Xvivo System’s Modular Design


Xvivo System pic
Xvivo System

Pediatric surgeon Mark Holterman, MD, has over two decades of experience. At present, Dr. Mark Holterman applies his expertise as a professor at the University of Illinois College of Medicine at Peoria and as an attending physician at OSF Saint Francis Medical Center, where he was co-surgeon on the first trachea transplant in a small child ever completed.

A nine-hour operation, the transplant was performed on a 32-month-old Korean toddler who was born without a developed trachea. In addition to extensive clinical and scientific expertise, the operation relied on an engineered stem cell-based trachea, a nanofiber tracheal scaffold and bioreactor, and the Biospherix Xvivo cell incubation and processing system.

The Xvivo is a closed system, featuring closed hoods and closed cell incubators, that enables the growth and storage of cell cultures. The system, which is modular, can be configured in hundreds of different ways. For example, the simplest format (stage 1) might feature a single closed hood and a single incubator. Stage 2 could add an additional incubation chamber, a microscope station, and other third-party add-ons such as a cell separator. The third stage could include an unlimited number of additional incubators while also incorporating more hoods and other stations.

Mark J. Holterman, Medical

Advantages of Ethically Sourced Fetal Stem Cells in Medical Research

Alliance for the Advancement of Cellular Therapies pic
Alliance for the Advancement of Cellular Therapies

Practicing in Peoria at the University of Illinois College of Medicine, Mark Holterman, MD, is a longtime pediatric surgeon with a focus on stem cell research. Also the cofounder of the Alliance for the Advancement of Cellular Therapies, Dr. Mark Holterman does not employ embryonic stem cells in his work. Rather, he coordinates research projects that center on ethically sourced fetal stem cells from grieving parents who have lost children through miscarriage.

An article presented by the U.S. National Library of Medicine at the National Institutes of Health focuses on the potential of fetal stem cells as vital tools in investigating diverse aspects of cell biology. In particular, they hold promise in therapeutic applications such as ex vivo gene therapy and cell transplantation.

Fetal stem cells can be isolated from a variety of fetal tissues, as well as bone marrow and fetal blood. The latter substance is particularly rich in hemopoietic stem cells, with first-trimester fetal blood also containing valuable non-hemopoietic mesenchymal stem cells. Advantages of fetal stem cells over embryonic stem cells include their status as “less ethically contentious.” They also offer the benefit of greater differentiation potential, as compared with adult stem cells.